Peter A. Thompson - 27 Jun 2025 Form 4 Insider Report for Corvus Pharmaceuticals, Inc. (CRVS)

Role: Director, 10%+ Owner
Signature: /s/ Peter A. Thompson
Issuer symbol: CRVS
Transactions as of: 27 Jun 2025
Net transactions value: -$0.2552
Form type: 4
Filing time: 01 Jul 2025, 21:17:05 UTC
Previous filing: 27 Jun 2025
Next filing: 26 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Thompson Peter A.	Director, 10%+ Owner	C/O CORVUS PHARMACEUTICALS, INC., 901 GATEWAY BOULEVARD, THIRD FLOOR, SOUTH SAN FRANCISCO	/s/ Peter A. Thompson	01 Jul 2025	0001357522

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRVS	Common Stock	Exercise of in-the-money or at-the-money derivative security	$4,891,894	+1,397,684	+20%	$3.50	8,341,338	27 Jun 2025	See Footnotes	F2, F3
transaction	CRVS	Common Stock	Sale	$4,891,894	-1,176,332	-14%	$4.16	7,165,006	27 Jun 2025	See Footnotes	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRVS	Common Warrants (right to buy)	Exercise of in-the-money or at-the-money derivative security	$0	-1,397,684	-100%	$0.000000	0	27 Jun 2025	Common Stock	1,397,684	$3.50	See Footnotes	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On June 27, 2025, OrbiMed Private Investments V, LP ("OPI V") exercised common warrants ("Warrants") to purchase 1,397,684 shares of the Issuer's Common Stock for $3.50 per share. OPI V paid the exercise price on a cashless basis, resulting in the Issuer withholding 1,176,332 of the Warrant shares to pay the exercise price and issuing to OPI V the remaining 221,352 shares.
F2	These securities are held of record by OPI V. OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V. The Reporting Person is a member of Advisors.
F3	Each of the Reporting Person, OrbiMed Advisors, and GP V disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.